
MetLife (MET) Stock Forecast & Price Target
MetLife (MET) Analyst Ratings
Bulls say
MetLife has demonstrated resilience in its financial performance with a diverse business model, benefiting from scale and a wide array of products across its five segments, which collectively contribute to its earnings stability. The anticipated recovery in variable investment income (VII) from 25% of normal in 2023 to 75% in 2024 is projected to generate an additional $300-$325 million, bolstering the company's earnings further. Additionally, the expansion in voluntary benefits within the Group Benefits segment and the improvement in retirement spreads highlight MetLife's strong positioning in the insurance market and potential for continued growth.
Bears say
The analysis presents a negative outlook for MetLife's stock primarily due to anticipated downward adjustments in earnings per share (EPS), which are projected to be 3.5% below consensus estimates for 2024. The company is facing an estimated headwind of $300-325 million to Retirement and Income Solutions (RIS) earnings as interest rate caps roll off, along with expected base spread compression leading to further EPS declines of around $0.20 per share. Additionally, the reduction in price targets reflects a shift in the earnings multiple, indicating a cautious stance influenced by the expected challenges in key segments, particularly Group Benefits and overall RIS profitability.
This aggregate rating is based on analysts' research of MetLife and is not a guaranteed prediction by Public.com or investment advice.
MetLife (MET) Analyst Forecast & Price Prediction
Start investing in MetLife (MET)
Order type
Buy in
Order amount
Est. shares
0 shares